JP2021535164A5 - - Google Patents

Info

Publication number
JP2021535164A5
JP2021535164A5 JP2021511547A JP2021511547A JP2021535164A5 JP 2021535164 A5 JP2021535164 A5 JP 2021535164A5 JP 2021511547 A JP2021511547 A JP 2021511547A JP 2021511547 A JP2021511547 A JP 2021511547A JP 2021535164 A5 JP2021535164 A5 JP 2021535164A5
Authority
JP
Japan
Application number
JP2021511547A
Other languages
Japanese (ja)
Other versions
JP7447089B2 (ja
JPWO2020047447A5 (https=
JP2021535164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049118 external-priority patent/WO2020047447A1/en
Publication of JP2021535164A publication Critical patent/JP2021535164A/ja
Publication of JP2021535164A5 publication Critical patent/JP2021535164A5/ja
Publication of JPWO2020047447A5 publication Critical patent/JPWO2020047447A5/ja
Priority to JP2024028682A priority Critical patent/JP7825650B2/ja
Application granted granted Critical
Publication of JP7447089B2 publication Critical patent/JP7447089B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021511547A 2018-08-31 2019-08-30 心筋サルコメア阻害剤 Active JP7447089B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024028682A JP7825650B2 (ja) 2018-08-31 2024-02-28 心筋サルコメア阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726162P 2018-08-31 2018-08-31
US62/726,162 2018-08-31
PCT/US2019/049118 WO2020047447A1 (en) 2018-08-31 2019-08-30 Cardiac sarcomere inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024028682A Division JP7825650B2 (ja) 2018-08-31 2024-02-28 心筋サルコメア阻害剤

Publications (4)

Publication Number Publication Date
JP2021535164A JP2021535164A (ja) 2021-12-16
JP2021535164A5 true JP2021535164A5 (https=) 2022-10-18
JPWO2020047447A5 JPWO2020047447A5 (https=) 2022-10-18
JP7447089B2 JP7447089B2 (ja) 2024-03-11

Family

ID=67953902

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511547A Active JP7447089B2 (ja) 2018-08-31 2019-08-30 心筋サルコメア阻害剤
JP2024028682A Active JP7825650B2 (ja) 2018-08-31 2024-02-28 心筋サルコメア阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024028682A Active JP7825650B2 (ja) 2018-08-31 2024-02-28 心筋サルコメア阻害剤

Country Status (22)

Country Link
US (4) US11414424B2 (https=)
EP (1) EP3843842A1 (https=)
JP (2) JP7447089B2 (https=)
KR (1) KR20210068422A (https=)
CN (2) CN112867539B (https=)
AR (1) AR116283A1 (https=)
AU (1) AU2019328556B2 (https=)
BR (1) BR112021003496A2 (https=)
CA (1) CA3110237A1 (https=)
CL (1) CL2021000481A1 (https=)
CO (1) CO2021003115A2 (https=)
EA (1) EA202190657A1 (https=)
EC (1) ECSP21016009A (https=)
IL (2) IL315709A (https=)
MA (1) MA53491A (https=)
MX (1) MX2021002199A (https=)
NZ (1) NZ773016A (https=)
PH (1) PH12021550400A1 (https=)
SG (1) SG11202101769YA (https=)
TW (1) TWI848972B (https=)
UY (1) UY38358A (https=)
WO (1) WO2020047447A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
KR20210054510A (ko) 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도
JP7447089B2 (ja) 2018-08-31 2024-03-11 サイトキネティックス, インコーポレイテッド 心筋サルコメア阻害剤
US12516016B2 (en) * 2020-03-11 2026-01-06 Sheldon Cao GPX4 inhibitors, pharmaceutical compositions thereof, and their use for treating GPX4-mediated diseases
CA3190060A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
EP4215525A4 (en) * 2020-09-17 2024-08-21 Zhejiang Hisun Pharmaceutical Co., Ltd. Piperazine derivative, preparation method therefor and use thereof
US20240010639A1 (en) * 2020-11-20 2024-01-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
MX2023010125A (es) 2021-03-04 2023-09-11 Cytokinetics Inc Inhibidores del sarcomero cardiaco.
US20230338378A1 (en) 2022-04-26 2023-10-26 MyoKardia, Inc. Methods of Administering Myosin Inhibitors
KR20250119513A (ko) 2022-09-02 2025-08-07 싸이토키네틱스, 인코포레이티드 5-(3,4-디플루오로벤질)-8-((1r,4r)-4-메틸시클로헥실)-6,9-디옥소-2,5,8-트리아자스피로[3.5]노난-2-카르브알데히드의결정질 형태
WO2025096779A2 (en) 2023-11-01 2025-05-08 Bristol Myers Squibb Company Methods of treatment with a myosin inhibitor using protein levels

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5919785A (en) * 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
KR100595922B1 (ko) 1998-01-26 2006-07-05 웨인 웨스터만 수동 입력 통합 방법 및 장치
WO2003059265A2 (en) * 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
CA2511970C (en) 2003-01-14 2012-06-26 Cytokinetics, Inc. Urea derivatives useful in the treatment of heart failure
EP1621540A4 (en) * 2003-04-21 2008-07-23 Ono Pharmaceutical Co HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
MX2007006230A (es) * 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
RU2318818C1 (ru) * 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
IL295547A (en) 2015-01-22 2022-10-01 Myokardia Inc Piperidine-4-methylsulfonyl-modified urea compounds for the treatment of dilated cardiomyopathy (dcm)
BR112018012390B1 (pt) 2015-12-17 2023-03-14 Syngenta Participations Ag Derivados de oxadiazol microbiocidas
EP3390398A1 (en) 2015-12-18 2018-10-24 Syngenta Participations AG Microbiocidal oxadiazole derivatives
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
WO2018089433A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7447089B2 (ja) 2018-08-31 2024-03-11 サイトキネティックス, インコーポレイテッド 心筋サルコメア阻害剤
KR20210054510A (ko) 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도
HRP20240200T1 (hr) 2019-07-17 2024-04-26 Cytokinetics, Inc. Oralne formulacije inhibitora kardijskih sarkomera
EP3999180B1 (en) 2019-07-17 2024-05-08 Cytokinetics, Inc. Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
CN114945372A (zh) 2019-11-10 2022-08-26 迈奥卡迪亚公司 用肌球蛋白调节剂的治疗方法
CA3190060A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
CN114456163B (zh) 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843B (zh) 2020-11-19 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
US20240010639A1 (en) 2020-11-20 2024-01-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
CN114539257B (zh) 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
TW202227402A (zh) 2020-11-24 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 嘧啶二酮類衍生物、其製備方法及其在醫藥上的應用
MX2023010125A (es) 2021-03-04 2023-09-11 Cytokinetics Inc Inhibidores del sarcomero cardiaco.
KR20250119513A (ko) 2022-09-02 2025-08-07 싸이토키네틱스, 인코포레이티드 5-(3,4-디플루오로벤질)-8-((1r,4r)-4-메틸시클로헥실)-6,9-디옥소-2,5,8-트리아자스피로[3.5]노난-2-카르브알데히드의결정질 형태

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)